알지노믹스

476830KOSDAQ자연과학 및 공학 연구개발업

57.7 / 100

Reference Date: 2026-04-13

Financial Score23.5 / 40

News Sentiment14.2 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit metrics are weak. Slightly down 2.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Aljonoomics is a biotech company that develops new drugs using platform technology, leveraging RNA trans-splicing ribozyme to target and replace specific RNA sequences with therapeutic genes. The company generates revenue through technology licensing and focuses on developing gene therapy treatments for genetic diseases and cancer, including hepatocellular carcinoma.

Number of Employees

39people

Average Salary

193.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

—Industry Average -32.113.5Point

Debt Ratio

1.62Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.0 / 3

Avg ▲1.8% (2-year basis)

ROE Trend

2.0 / 4

Detailed News Sentiment

15 totalPositive 3Neutral 7Negative 0Average Sentiment Score 60

Detailed Momentum

52-week position6.0Point

52w upper range (67%)

Current 188,500Won52-week high 236,00052-week low 90,000

1-month return2.0Point

1m -2.13% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-10
Neutral주식등의대량보유상황보고서(약식)2026-04-09
Neutral주식등의대량보유상황보고서(약식)2026-04-01
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral정기주주총회결과2026-03-31